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The modulation of actin dynamics via atypical Protein Kinase-C activated Cofilin
regulates metastasis of colorectal cancer cells
S M Anisul Islam, Rekha Patel, Raja Reddy Bommareddy, Khandker Mohammad Khalid, and Mildred AcevedoDuncan
Department of Chemistry, University of South Florida, Tampa, FL, USA
ABSTRACT

ARTICLE HISTORY

Colorectal cancer (CRC) is the third most common cancer in the United States. The exact mechanism of
CRC cells metastasis is poorly understood. Actin polymerization is thought to be an initial step in the
cancer cell motility cycle which drives the formation of cell protrusions and defines the direction of
migration. Cofilin, a significant actin-regulating molecule, regulates the migration of cancer cells by the
formation of lamellipodia and filopodia, however, little is known about the upstream regulation of cofilin.
In this study, the effect of atypical Protein Kinase C (atypical PKC) on Cofilin activity in CRC was studied.
This study demonstrates that the atypical PKC inhibition impedes the metastasis of CRC cells by
increasing phospho-Cofilin (S3) and changing actin organization.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers of the gastrointestinal tract. The current therapeutic
options for treating CRC are confined to surgical removal
of the tumor, chemotherapy, and radiation. Metastasis is an
essential factor in a patient’s death with CRC [1]. The
assembly of actin filaments at the leading edge drives the
movement of the cells by generating cell protrusion force
during invasion and migration [2]. Actin-binding proteins
(ABP) regulate actin filaments dynamics by controlling
polymerization and depolymerization and the formation
of actin-based bundles and cellular protrusions [3,4].
A significant member of ABP superfamily known as
Cofilin/actin depolymerizing factor (ADF) plays an essential role in actin-filaments turnover by depolymerizing and
severing filamentous actin [5–7]. The regulation of Cofilin
activity depends on its phosphorylation and dephosphorylation [8]. The phosphorylation of Cofilin at Serine-3 by
different kinases such as LIM kinase 1 (LIMK1) and LIM
kinase 2 (LIMK2) make it unable to bind and sever filamentous actin [9,10]. However, phosphatases such as
Slingshot (SSH), Protein Phosphatase1 (PP1), Protein
Phosphatase 2A (PP2A), Protein Phosphatase 2B (PP2B),
and chronophin dephosphorylate Cofilin at Serine 3 to
render it active [11–13].
Although the exact mechanism of migration and chemotaxis is complex and far from complete elucidation, the
Protein Kinase C (PKC) family of enzyme drew significant
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attention over the last few decades as a critical regulator of
chemotactic cell migration [14,15]. PKC is a large family of
phospholipid-dependent Serine/Threonine kinases activated by different extracellular molecules [16]. Based on
the domain structures and regulation, there are three classes
of PKCs: (1) Classic PKC, include PKC-α, βI, βII and γ,
contain a phospholipid binding domain (C1) and a Ca2+
binding domain (C2), hence, are regulated by Ca2+ and
lipid secondary messengers such as diacylglycerol; (2)
Novel PKC, include PKC-δ, η, θ, and ε, contain phospholipid binding domain (C1) but lack Ca2+ binding domain,
thus, regulated by lipid but insensitive to Ca2+; and (3)
Atypical PKC, include PKC-ι, and PKC-ζ, neither have
lipid binding domain nor Ca2+ binding domain, therefore
insensitive to both diacylglycerol and Ca2+ [17].
Phosphorylation of many downstream substrates by
PKC regulates the growth, transcriptional regulation,
learning, memory, polarity, chemotaxis, migration,
and adhesion in different cell types [18–20]. For
instances, PKC-α mediated phosphorylation of integrin
α6β4 drove the mobilization of integrin from hemidesmosomes and associated with actin cell protrusion to
regulate the migration of cancerous cells [21]. In MDAMB-468 breast cancer cells, PKC-δ plays an essential
role in the persistent migration of EGFR overexpressed
cells by controlling the EGF dependent phosphorylation of the light chain of myosin [22]. PKC-ι controls
cell cycle progression by regulating CAK/CDK7 in
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glioma cells [23]. Moreover, PKC-ι is also involved in
the metastasis and angiogenesis of pancreatic cancer via
stimulating Rac1/MEK/ERK pathway [24]. Likewise,
PKC-ζ regulates the survival, growth, and polarity of
the cancer cells by regulating NF-ĸb and Jak/Stat signaling pathway [25]. Additionally, PKC-ζ converges
with the Receptor Tyrosine Kinase (RTK), and
G-protein coupled receptor-mediated chemotactic signals in breast and lung cancers cell lines [26,27].
In this study, we used two novel inhibitors of atypical
PKC: ICA-I and ζ-Stat (Figure 1), selective for PKC-ι and
PKC-ζ respectively, to examine the metastatic behavior
of CRC cells. We established that the atypical PKC modulates actin cytoskeleton in colorectal cancer cells by
regulating Cofilin via a slingshot isoform, SSH2. Upon
PKC-ι and PKC-ζ knockdown, there was an increased
expression of p-Cofilin (S3) which was directly correlated to the metastatic behavior of the cancerous cells.
Our data indicate that the inhibition of atypical PKC will
be a robust therapeutic approach as it disrupts the actin
dynamics of the CRC cells.

Materials and method
Antibodies and reagents
ICA-I and ζ-Stat were obtained from United Chem
Resource (Birmingham, AL) and the National Cancer
Institute (NCI) respectively. Anti-PKC-ι (610176) and
anti-E-Cadherin (619494) antibodies were purchased
from BD Biosciences. The antibodies to anti-Phospho
PKC-ζ (T410) (2060), anti-PKC-ζ (9372), anti-SSH1
(13578), anti-Caspase-3 (9662), anti-Cleaved Caspase-3
(9579), anti-PARP (9532), anti- Cleaved PARP (5625), antiBCL-2 (2872), anti-BCL-XL (2764), anti-ARP2 (5614),
anti-α-Tubulin (2125), and anti-GAPDH (5174) were
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procured from Cell Signaling Technology. The antibodies
obtained from Santa Cruz Biotechnology were anti-Cofilin
(sc-53934), anti-Phospho Cofilin (S3) (sc-271921), antiSurvivin (sc-419153). Anti-Phospho PKC-ι (T555)
(ab5813), anti-Phospho PKC-ζ (T560)(ab59412), and
Phalloidin iFluor 594 conjugate (ab176757) were purchased
from Abcam. The anti-SSH2 (20674–1-AP) antibody was
obtained from ProteinTech. The anti-Phospho SSH (S978)
(SP3901) antibody was purchased from ECM Biosciences.
The G-actin/F-actin in-vivo assay Biochem kit (BK037) was
purchased from Cytoskeleton Inc. The siRNAs, siPRKCI
(SR321426), and siPRKCZ (SR321432) were procured from
Origene. The cell dissociation solution, coating buffer and
basement membrane extract (BME) were obtained from
Trevigen Inc. The HyQtase cell detachment solution
(SV3003001) was procured from Hyclone Inc. Calcein
AM (C3100MP) was obtained from Molecular Probes.
Enhanced Chemiluminescence (Super Signal West Pico
Chemiluminescent Substrate) (34580) was Purchased
from Pierce. Horseradish peroxidase (HRP) conjugated
goat anti-mouse (1706516), and goat anti-rabbit
(1706515) secondary antibodies were bought from BioRad Laboratories. Water-soluble tetrazolium salts (WST1) (11644807001) reagent was bought from Sigma-Aldrich.
Eagle’s minimum essential medium was obtained from
Corning. Anti-β-actin (MA5-15739-HRP) antibody, F12K
media, and Trypsin-EDTA (ethylene diamine tetra-acetic
acid) were purchased from Thermo Fisher Scientific.

Cell lines and subculture
The healthy colorectal epithelial cells, CCD18CO, and
metastatic CRC cell lines, LoVo and RKO, were obtained
from American Type Tissue Culture Collection (ATCC).
The CCD18CO and RKO cells were sub-cultured and

b

a

ICA-I (Nucleoside analog)

ζ-Stat

Figure 1. Structures of Atypical PKC inhibitors. (a) ICA-I (nucleoside analog, 5-amino-1-((1S,2R,3S,4S)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl)-1H-imidazole-4-carboxamide). (b) ζ-Stat (8-hydroxynaphthalene-1,3,6-trisulfonic acid).
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maintained in Eagle’s Minimum Essential Medium
(EMEM), and LoVo was sub-cultured and maintained in
F12K media. All the flasks were supplemented with 10%
Fetal Bovine Serum (FBS) and 1% antibiotics (Penicillin
10 U/ml and streptomycin 10 mg/ml). Cells were incubated
at 37°C and 5% CO2. Cells were used for the experiments
a few days following subculture at 70–80% confluent.
In-vitro treatment of normal colon and metastatic
CRC cells with ICA-I and ζ-stat
The setup for this analysis was the same as our previously published study [28].
Cell lysates preparation and immunoblot analysis
The experiments were performed as per the experimental procedures described in our previous article [28].
Transwell invasion and migration assay
After starving for 24 hours, cells were detached from
the flask’s surface using cell detachment solution and
re-suspended in serum-free media followed by plating
(2.5 × 104) into the upper chamber of 96 wells
Transwell permeable support (pore size: 8 μm) that
has been coated with 0.3x Basement Membrane
Extract (BME). Serum containing media was loaded
into the receiver plate (lower chamber) as
a chemoattractant. LoVo and RKO cells at the upper
chamber were treated with 7µM of either ICA-I or ζStat for six days and three days respectively. Following
treatment, the invasive cells at the lower chamber were
stained with Calcein AM, a fluorescent dye, and quantified using Bio-Tek microplate reader (Winooski, VT)
at excitation and emission wavelengths of 485/520 nm.
For migration assay using transwell plate, the same
procedure of invasion study was followed, but the
transwell inserts were not coated with BME solution.
Scratch wound healing assay
This assay is performed following the experimental
design as our previous work [28].
Crystal violet staining
Cells were serum starved for 24 hours, followed by
detachment and plating (2.5 × 104) into the upper
chamber of 96 wells Transwell permeable support
(pore size: 8 μm) coated with and without 0.3x
Basement Membrane Extract (BME) for studying
migration and invasion respectively. Serum (10%)

containing media was loaded into the receiver plate
(lower chamber) as a chemoattractant. LoVo and
RKO cells at the upper chamber were treated with
7µM of either ICA-I or ζ-Stat for six days or three
days respectively. The invasive cells in the lower chamber were then fixed with 4% paraformaldehyde, stained
with 1% crystal violet in 2% ethanol, washed with water
and photographs were captured after drying.
Phalloidin staining of filamentous (F) actin
CRC cells were grown in 2-wells chamber slides coated
with poly D-lysine (1 mg/ml). Following treatment for
three consecutive days with 7 μM of either ICA-I or ζStat, cells were fixed with 4% paraformaldehyde.
F-actin was subsequently stained with 1X PhalloidiniFluor 594 in 1% bovine serum albumin (BSA)phosphate buffered saline (PBS) solution for an hour
at room temperature. Cells were washed, counterstained with DAPI and examined under Nikon
MICROPHOT-FX fluorescence microscope (Ex/
Em = 590/618) and photographs were captured using
ProgRes®Capture 2.9.0.1.
4΄,6-diamidino-2-phenylindole (DAPI) staining
The procedures followed was identical as in our previously published study [28].
Filamentous (F) and globular (G) actin fractionation
Fractionation of F-actin and G-actin was performed
according to manufacturer instruction with G-Actin/
F-actin in-vivo assay kit. Briefly, CRC cells were
grown in 100 mm tissue culture plate and treated
with 7 μM of either ICA-I or ζ-Stat for three consecutive days. Cells were then lysed with cell lysis buffer
containing F-actin stabilizing buffer to extract G-actin,
followed by extraction of F-actin. The F-actin was then
depolymerized using an F-actin depolymerizing buffer
to convert F-actin to G-actin. F/G fractions were
resolved using the 10% SDS-PAGE and immunoblotted
using Actin antibody. The intensity of bands from
different fractions was then quantified by densitometry.
Transfection of metastatic CRC cells and RNA
interference
Approximately, 1 × 106 CRC cells were inoculated into
60 mm tissue culture plate. Twenty-four hours post-plating,
cells were transfected using Si Tran 1.0 (Origene, Rockville,
MD) according to the manufacturer instructions. The
siPRKCI (sequence 5ʹ-UUAUGAGCUAAACAAGGA
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UUCUGAA-3ʹ) and siPRKCZ (sequence 5ʹ-AGUAGAG
CACAAGAACGAGGACGCC-3ʹ) were used to transfect
the LoVo and RKO cells. Additionally, cells were also
transfected with universal scrambled negative control
sequence to ensure the targeted gene silencing. Following
forty-eight hours of incubation, cells were harvested and
subjected to immunoblot analysis to determine the expression of PKC-ι, PKC-ζ, SSH1, SSH2, Cofilin and
pCofilin (S3).
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serum starved slow growing normal and colorectal cancerous cells. Our data indicated that the expression of PKC-ζ
was higher in rapidly growing CRC cells (both LoVo and
RKO) compared to the healthy cell (CCD18CO).
Additionally, PKC-ι was also found to be elevated in fastgrowing metastatic RKO cell. However, the expression
profile of atypical PKC in the normal cell was not as robust
as in cancerous cells (Figure 2). These results suggest that
the atypical PKC might play an essential role in CRC cells
progression.

Densitometry
The intensity of each band was quantified using 1D analysis
software, Alpha View (Protein Simple, San Jose, California)
and Image Studio Lite Ver 5.2 (LI-COR Biosciences,
Lincoln, NE). The background intensity was subtracted
from each band to quantify the correct intensity.
Statistical analysis
To determine the Statistical significance of the data, the
results were expressed as the Mean ± Standard error of the
mean (S.E.M) of at least three independent experiments.
p values were calculated based on Student t-test (two-tailed)
and one-way ANOVA using GraphPad Prism 7.04 or
Microsoft Excel software. A p value of < 0.05 was considered significant.

Results
Expression profile of atypical PKC in rapidly
growing and serum starved healthy and malignant
colon cells
To establish the role of atypical PKC in colorectal cancer the
very first experiment performed was the determination of
atypical PKC expression profile in rapidly growing and

ICA-I and ζ-stat inhibit PKC-ι and PKC-ζ respectively
The amino acids sequences of PKC-ι and PKC-ζ are highly
identical (72% homologous) [17]. Hence, the determination of selectivity of the inhibitors used was necessary.
Therefore, cells (both normal and malignant) were treated
with 7 μM of either ICA-I or ζ-Stat and examined for the
expression of atypical PKC. Our data revealed that with the
treatment of ζ-Stat, the level of both phospho and Pan PKCζ decreased by more than 30% (p < 0.05) in CRC cells.
Additionally, ICA-I brought a significant reduction in the
Phospho PKC-ι (T555) by more than 45% (p < 0.05) in
RKO cells but not in LoVo. In contrast, the inhibitors did
not induce any notable change in the atypical PKC levels of
the healthy cell (Figure 3(a,b)). These observations indicate
that the inhibitors are specific for the respective atypical
PKC in CRC cells and their inhibition could be used as
a therapeutic target to encounter colorectal cancer
progression.

Atypical PKC regulates CRC cells migration and
invasion
Our previous study showed that PKC-ζ regulates the
growth of colorectal cancers cells via PKC-ζ/Rac1/Pak1/

Figure 2. Expression profile of atypical PKCs in normal and metastatic CRC cells. Cells were grown with and without serum
over a period of 48 hours. Whole cell lysate was prepared and an equal amount of protein from the lysates was subjected to western
blot analysis, followed by examining PKC-ι and PKC-ζ expression in rapidly growing and serum starved cells. β-Actin was used as a
loading control. N = at least 3 independent experiments.
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a

b

Figure 3. atypical PKC inhibitors reduced the expression of both phospho and pan level of atypical PKCs. (a) Western blot
analysis for the effect of ICA-I and ζ-Stat on PKC-ι and PKC-ζ in CCD18CO, LoVo and RKO cells following three days of treatment. (b)
The bar graphs illustrate densitometry of total and phospho atypical PKC proteins as a function of atypical PKC inhibitors. Cells were
grown in 100 mm cell culture plate followed by treatment with 7 μM of either ICA-I or ζ-Stat. Mean ± S.E.M.; N = at least 3 separate
experiment; * = 0.05, ** = 0.02, *** = 0.01(indicates p value).

β-Catenin pathway [28,29]. Our next target was to
examine the role of atypical PKC in another hallmark
of cancer, metastasis. To gain insight into the antimigratory and anti-invasive potential of atypical PKC
inhibitors, we performed three different strategies:
scratch wound healing assay, transwell migrationinvasion assay and crystal violet staining of the cells
passed through BME. The data from scratch assay
revealed that the treatment (six days) of LoVo with ζStat (at 7 μM) decreased the rate of wound closure by
approximately 45% (p< 0.05) compared to control. The
treatment (three days) of RKO with both atypical PKC
inhibitors (ICA-I and ζ-Stat, at 7 μM) showed a prolonged rate of wound closure (approximately 35%,

p< 0.02) compared to control. However, treatment
with ICA-I did not bring any significant effect in
LoVo (Figure 4(a)). Similarly, the transwell migration
and invasion assay results showed that atypical PKC
knockdown significantly inhibited the chemotactic
migration of LoVo (approximately 40%, p < 0.05) and
RKO (approximately 40%, p < 0.01) CRC cells (Figure 4
(b)). According to our transwell invasion and crystal
violet staining assays, the treatment (at 7 μM) of both
ICA-I and ζ-Stat decreased the number of RKO cells
that invaded through the BME (approximately 45%,
p < 0.01), likewise, in response to ζ-Stat, the number
of LoVo cells passed into the lower chamber of transwell plate through the BME reduced remarkably (about
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50%, p < 0.02) (Figure 4(c)). E-Cadherin, a cell adhesion molecule, is often downregulated and considered
to be a crucial mediator of epithelial to mesenchymal
transition (EMT) during metastasis [30]. Additionally,
there was an elevated expression of E-Cadherin, as
a function of PKC-ζ inhibition in LoVo, and PKC-ι
and PKC-ζ inhibition in RKO (Figure 4(d,e)). These
data indicate that atypical PKC is a crucial regulator in
CRC migration and invasion.
Atypical PKC controls cofilin/p-cofilin ratio via
slingshot
Our next target was to study possible protein/s that drives
the changes in the cytoskeletal phenotype of CRC cells.
Since actin filaments are the major components of cell
cytoskeleton, we decided to test the essential actin binding
candidate namely Cofilin as it severs F-actin to promote
polymerization. Our results showed that the treatment of ζStat reduced the amount of total Cofilin by more than 30%
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(p < 0.05) and increased the Phospho Cofilin at S3 by 50%
(p < 0.05) in both CRC cells. Additionally, ICA-I showed
the similar shift in RKO but not in LoVo (Figure 5(a,b)).
Slingshot proteins are significant phosphatases that act on
Cofilin activity [31]. We established that the phosphatase
SSH2 levels in LoVo and RKO decreased dramatically (50%
in LoVo, p < 0.02; and 30% in RKO, p < 0.05) with 7 μM ζStat, however, the phospho SSH at 978 and SSH1 levels did
not change significantly. Similarly, 7 μM ICA-I decreased
the SSH2 expression by 42% (p < 0.05) in RKO but not in
LoVo. Conversely, CCD18CO healthy colon cells were
insensitive to atypical PKC knockdown treatment (Figure
5A, 5B). As a proof of concept, we also tested the expression
of PKC-ι, PKC-ζ, SSH1, SSH2, pCofilin(S3) and Cofilin in
siPRKCI and siPRKCZ transfected CRC cells. Our findings
illustrated that the siPRKCI and siPRKCZ transfected CRC
cells showed a similar trend in the expression of targeted
proteins as in cells treated with ICA-I and ζ-Stat (Figure 5(c,
d)). These data suggest that atypical PKC stimulates actin
remodeling in CRC cells by regulating Cofilin via SSH2.

a

b

Figure 4. Atypical PKCs regulate migration and invasion of colorectal cancer cells. (a) Metastatic LoVo and RKO cells were
grown to approximately 90% confluency and subjected to wound healing assay by making a scratch using sterile 100 µl pipette tip
along with atypical PKC inhibition treatment. (b) The bar charts are representing the number of cells migrated in transwell plate
against chemotactic gradient. (c) Crystal violet stained cells, and bar charts are showing the number of CRC cells passed through
BME into the lower chamber of transwell plate. (d) Expression of E-cadherin, a cell adhesion protein, in treated healthy and CRC cells.
(e) Densitometry of E-cadherin expression. All the experiments were performed at least three times. Mean ± S.E.M. * represents p
value (* < 0.05, ** < 0.02, *** < 0.01).
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c

d

e
Band intensity (arbitrary unit)

Effect of aPKC inhibitors on healthy and cancerous
colorectal cells (E-Cadherin)
6.0

4.0

*

***

***

*

2.0

0.0

*

***

CCD18CO

LoVo

RKO

Figure 4. (Continued)

a
b

c
d

Figure 5. Atypical PKC controls actin organization by regulating Cofilin via SSH2 in CRC cells. (a) Immunoblot analysis is showing the
effect of ICA-I and ζ-Stat in healthy and CRC cells following three days of treatment. Proteins tested were pSSH (S978), SSH1, SSH2, pCofilin (S3)
and Cofilin. (c) The expression of PKC-ι, PKC-ζ, SSH1, SSH2, pCofilin (S3) and Cofilin in siPRKCI and siPRKCZ transfected CRC cells. (B & D) The bar
charts are representing the corresponding band intensities. α-tubulin was probed as a loading control. All experiments were performed for at
least 3 independent times. Mean ± S.E.M and * represents p value (* < 0.05, ** < 0.02, *** < 0.01).
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a

b

c

Figure 6. Atypical PKC regulates filamentous actin content and actin dynamics. Cells were treated with atypical PKC inhibitors
for 72 hours. (A, B) Cells were stained with Phalloidin iFluor 594 and counter stained with DAPI. Original magnification: 20X and
scale bars represent 10 μm. (c) F-actin and G-actin were fractionated from control and treated cells followed by western blot analysis.
The F and G-actin were quantified using densitometry followed by determining F/G actin ratio. (Mean ± S.E.M, N = at least 3
independent experiments, * indicates p value where * < 0.05, ** < 0.02, *** < 0.01).
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Atypical PKC controls filamentous actin and actin
dynamics
During chemotaxis, two crucial events are cytoskeleton
rearrangement and adhesion which are regulated by PKCζ [26]. To investigate how spreading and metastasis of the
CRC cells are affected by atypical PKC, actin filaments were
examined under the microscope with phalloidin conjugate
following atypical PKC inhibition. Down-regulation of
PKC-ζ provoked excellent actin filaments organization in
both CRC cells compared to control cells that contained less
organized actin filament (Figure 6(a,b)). Likewise, ICA-I
significantly changed the actin filaments organization in
RKO cell as well (Figure 6(b)). After observing changes in
cells migratory behavior and actin filaments, we also
decided to study actin dynamics. Hence, we determined
the fractions of F-actin and G-actin in treated and untreated
LoVo ad RKO cells. In response to PKC-ζ knockdown, the
ratio of F/G actin increased significantly (approximately
35%, p < 0.02) in both CRC cells (Figure 6(c)).
Additionally, inhibition of PKC-ι increased the F/G ratio
by 31% (p < 0.02) in RKO cell too (Figure 6(c)). These

Atypical PKC inhibition prevents the dendritic
branches by blocking ARP2
Actin-related protein 2, ARP2, resembles monomeric actin
and coordinately overexpressed with Cofilin in motile cells
[32]. ARP2 synergistically interacts with Cofilin to produce
dendritic nucleation which pushes the cell membrane
inducing cell protrusion and lamellipodia extension [33].
To establish the fate of branching structures of actin
filaments in atypical PKC knockdown cells, we examined
the expression of ARP2 in ICA-I and ζ-Stat treated cells.
Our data showed that the expression ARP2 decreased by
more than 50% (p < 0.02) in LoVo with the inhibition of
either PKC-ι or PKC-ζ. Additionally, ICA-I brought
a significant reduction (approx. 35%) of ARP2 levels in
RKO cell (Figure 7(a,b)). These results indicate that the
atypical PKC may also regulate dendritic nucleation in
motile CRC cells.

b
Band intensity (arbitrary unit)

a

results suggest that atypical PKC facilitates metastasis of
CRC cells by modulating actin dynamics.

Effect of aPKC inhibitors on healthy and cancerous
colorectal cells (ARP2)
3

**
***

2

**
1

*** **

0
CCD18CO

LoVo

RKO

Figure 7. Expression of actin related protein 2, ARP2 in normal and CRC cells. Cells were grown and treated with atypical PKC
inhibitors for three consecutive days. Equal amount of cell lysate was subjected to western blot analysis. (a) Expression of ARP2, an
actin nucleating protein in healthy and cancerous cells. α-Tubulin was used as a loading control. (b) The bar charts represent
corresponding band intensity. N = 3 independent experiments. Mean ± S.E.M. * represents p value (* < 0.05, ** < 0.02, *** < 0.01).

Figure 8. Effect of atypical PKC inhibitors on normal and malignant colorectal cells. CCD18CO, LoVo, and RKO cells (4 x103)
were plated in 96 wells plate and treated with 5 μM and 7 μM of either ICA-I or ζ-Stat for 72 hours followed by incubation with a
WST-1 reagent for 3 hours and determination of absorbance at 450 nm using microplate reader. The data represents N = at least 3
independent experiments, mean ± S.E.M. *** < 0.0009, and **** < 0.0001 (indicate p value).
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a

b

c

Figure 9. Atypical PKC inhibitors induce apoptosis in CRC cells. Cells were treated for 72 hours with 7 μM of either ICA-I or ζ-Stat.
Following treatment, (a) Cellular nuclei were visualized using DAPI. Original magnification 20X and scale bars represent 10 μm. The
white arrows are showing the cells undergoing apoptosis. (b) An equal amount of protein (40 μg) from cellular extracts of both
normal and CRC cells were separated by SDS-PAGE, followed by Western blot analysis with different pro and anti-apoptotic
antibodies. GAPDH was used as a loading control. (c) The bar charts represent the corresponding band intensities of apoptotic
and survival markers. N = 3, Mean ± S.E.M. * represents p value where * < 0.05, ** < 0.02 and *** < 0.01.
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Atypical PKC inhibitors hinder CRC cells viability
without affecting normal colon cells
To determine the effect of atypical PKC on colorectal
cell proliferation, both normal and cancerous cells were
treated with either 5 μM or 7 μM of either of the two
inhibitors (ICA-I and ζ-Stat) for three consecutive days.
The results showed that ζ-Stat reduced the viability of
cancerous cells (both LoVo and RKO) by approximately 45% at a dose of 7 μM (p< 0.0001) (Figure 8).
Likewise, the treatment of 7 μM ICA-I decreased the
cells viability of LoVo by 33% (p< 0.0009) and RKO by
46% (p< 0.0001) (Figure 8). However, the treatment
with atypical PKC inhibitors did not produce any significant cytotoxic effect on normal colon cell viability.
These data demonstrate that the atypical PKC inhibitors might be used to treat CRC cells without affecting
healthy colorectal cells.

Induction of apoptosis by atypical PKC inhibitors in
CRC cells
To establish whether the cells were undergoing programmed cell death with atypical PKC knockdown,
visualization of cellular nuclei using DAPI along
with the determination of expression of different
pro- and anti-survival proteins were investigated.
The data showed that with an ICA-I treatment of
7 μM for 72 hours, RKO cells exhibited notable
chromatin condensation and nuclear fragmentation
compared to control as visualized by nuclear staining with DAPI, likewise, to some extent, LoVo also
possessed fragmented cells (Figure 9(a)). On the
other hand, in response to ζ-Stat (7 μM) treatment,
both LoVo and RKO cells showed significant apoptotic bodies. Additionally, PKC-ζ inhibition reduced
the level of survival proteins, such as BCL-2 by
more than 35% (p < 0.02), BCL-XL by more than
45% (p < 0.01), and Survivin by more than 30% in
both CRC cells (Figure 9(b,c)). Similarly, PKC-ι
inhibition brought down the level of BCL-2, BCLXL, and Survivin by more than 35% (p < 0.05) in
RKO but not in LoVo. Moreover, Caspase-3 was
found to be active as proportional changes in the
expression of Cleaved and total Caspase-3 were
observed. Furthermore, changes in the expression
of PARP, a downstream nuclear substrate of
Caspase-3 activation [34], was also detected
(Figure 9(b,c)). However, no notable apoptotic
changes were observed in normal colorectal cells
with atypical PKC inhibition. Hence, these findings
indicate that the CRC cells undergo apoptosis in
response to anti-atypical PKC treatment.

Discussion
Our current understanding concerning PKCs recalls that
they are functionally pleiotropic protein kinases involved
in various parallel and cross signaling events that regulate
different cellular processes such as proliferation and
metastasis [35]. During carcinogenesis, PKCs are active
and found to be elevated in many cancers, such as breast,
lung, liver, colon, and prostate [36]. Most importantly,
each isoform of PKC family may act distinctively in the
biological system and tumorigenesis. Therefore, careful
dissection of PKC function and tailored intervention
strategy in cancer progression need to be established.
Colorectal adenocarcinoma is cancer that originates
from glands found in the wall of the colon and rectum
and accounts for 96% of CRC [37]. Thus, the rationale for
choosing LoVo and RKO in this study was that both cells
represent colorectal adenocarcinoma. Atypical PKC is
highly expressed in more than 120 colorectal adenocarcinoma tissue samples [38], likewise, in this study, PKC-ζ is
overexpressed in both CRC cells and PKC-ι in RKO cells
(Figure 2). The selectivity of the inhibitors in different
CRC cell lines was necessary because of high structural
similarity (72% identical) of atypical PKC isoforms. Our
data illustrated that ICA-I and ζ-Stat inhibited PKC-ι and
PKC-ζ, respectively (Figure 3(a,b)).
Previously, our published study showed that the PKC-ζ
regulate the growth and proliferation of CRC cells by
stimulating Rac1/Pak1/β-Catenin pathway [28,29]. In
this study, we evaluated the functional role of atypical
PKC in the metastasis of CRC cells. Firstly, we performed
two primary metastasis assays, namely scratch wound
healing assay and serum gradient induced chemotaxis
assay, using metastatic LoVo and RKO cells. In each
case, the treatment of atypical PKC inhibitors impaired
the migration and invasion of the CRC cells. Briefly, PKCζ inhibition blocked the metastasis of both CRC cells and
PKC-ι knockdown brought a significant reduction of
migration and invasion of RKO as indicated by our
scratch wound healing assay, crystal violet staining and
transwell migration-invasion assay (Figure 4(a-c)). In
LoVo, even though the knockdown of PKC-ι did not
bring any significant change in the scratch wound recovery assay (Figure 4(a)), a notable change was observed in
the serum gradient induced chemotaxis assay with the
treatment of ICA-I (Figure 4(b,c)). The exact reason for
this finding could not be deciphered. However, the inhibition of PKC-ζ induced the upregulation of E-Cadherin
in both CRC cells, whereas, only PKC-ι knockdown promoted the increased E-Cadherin levels in LoVo (Figure 4
(d,e)). Furthermore, our subsequent metastatic investigation of LoVo showed that only PKC-ζ could regulate the
metastasis of LoVo by modulating actin organization.

CELL ADHESION & MIGRATION

The crawling movement of metastatic cancerous
cells from one place to another is driven by the actin
polymerization and depolymerization. Cofilin is an
actin-binding protein (ABP) which regulates actin polymerization and the formation of migratory structures
of the cells, i.e., lamellipodia and filopodia to promote
directional cell movement [12]. Activated Cofilin has
been linked with metastatic glioblastoma, breast, pancreatic and ovarian cancer [39–41]. In addition, elevated expression of cofilin is also implicated in CRC
cells [42,43]. Moreover, constitutive Cofilin phosphorylation at serine-3 residue retards the ability of CRC
cells to metastasize [44]. Hence, we examined the
expression of both phospho and pan Cofilin in atypical
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PKC inhibitors pretreated CRC cells. Our data demonstrated that the inhibition of PKC-ζ reduced the expression of Cofilin in both LoVo and RKO, and the
knockdown of PKC-ι decreased Cofilin levels in RKO
as well. In addition, treatment of atypical PKC inhibitors increased the cellular level of Phospho-Cofilin (S3)
in both CRC cells (Figure 5(a,b)). Thus, our observation supports a possible role of atypical PKC in the
migration and invasion of CRC cells by impairing
downstream signals that regulate Cofilin.
In CRC, an exciting novel finding was that the phosphatase, SSH, an upstream regulator of Cofilin dephosphorylation, is also overexpressed [45]. Elevated levels of
SSH is not only associated with tumorigenesis but also

Figure 10. Atypical PKCs control actin cytoskeleton via Cofilin activation. The Cofilin pathway is activated by atypical PKC via Slingshot,
SSH. Phosphorylated Cofilin at serine-3 is inactive. Phosphatases such as SSH induces the dephosphorylation and activation of Cofilin. Activated
Cofilin can then sever the mother filaments and produced free barbed ends leading to the elongation of newly formed actin filaments which
are preferred for dendritic nucleation by ARP2/3 complex and globular actin. These newly formed structures push on the cell membrane to
promote protrusion and motility.
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a significant predictor of lymph node metastasis
[11,45,46]. In further agreement, in-vitro studies of pancreatic and breast cancer cell lines suggest that the tumorpromoting role of SSH is mainly due to its ability to
dephosphorylate Cofilin since the loss of SSH function
resulted in the decreased non-phosphorylated Cofilin and
metastatic ability of those cell lines [31,47]. With this
context, we examined two isoforms of SSH, SSH1, and
SSH2, in treated and untreated CRC cells as a function of
atypical PKC inhibition. Our results depicted that the
knockdown of atypical PKC did not change SSH1 levels,
but, resulted in the remarkable deactivation of SSH2 in
both CRC cell lines which were correlated to the reduced
level of activated Cofilin and increased level of phosphorylated Cofilin (Figure 5(a,b)). As a proof of concept,
CRC cells were also transfected with siRNA of PRKCI and
PRKCZ (genes for PKC-ι and PKC-ζ respectively). Our
observation showed a similar correlation among atypical
PKC, SSH2 and Cofilin expression in siRNA transfected
CRC cells as in atypical PKC inhibitors treated cells
(Figure 5(c,d)).
Since cofilin activity is pivotal for cellular actin filaments
polymerization/depolymerization and branching that ultimately leads to membrane protrusion and polarization, this
issue was further addressed by immunostaining F-actin and
measuring the level of F and G-actin in treated CRC cells.
We found that the actin filaments were nicely organized
around the cytoskeleton of treated LoVo cell with ζ-Stat and
treated RKO cell with both atypical PKC inhibitors (Figure
6(a,b)). Additionally, the ratio of F/G actin was increased
notably in both LoVo and RKO cells with the treatment of
atypical PKC inhibition (Figure 6(c)). Moreover, another
crucial step in invasion and protrusion is the formation of
branched dendritic actin network [48]. Cofilin partners
with ARP2 to stimulate the formation of dendritic structure
[48]. Our data illustrated that the inhibition of atypical PKC
in CRC cells reduced the level of ARP2 in treated cancerous
cells compared to both healthy colon cells and untreated
cancerous cells (Figure 7(a,b)). Moreover, the primary signaling molecules that drive the interaction of Cofilin and
ARP2 are small GTPases such as Rho, and Rac1 [49].
Previously, we found that the PKC-ζ associates and phosphorylates Rac1, hence, it may also facilitate the CofilinARP2 interaction as well. Therefore, the data presented
here have an established part of the mechanism of CRC
cells metastasis regulated by atypical PKC via Cofilin.
However, further in-vitro and in-vivo studies need to be
performed to fully elucidate the metastatic role of atypical
PKC in the regulation mechanism of Cofilin by slingshot.
Furthermore, we also evaluated the effect of atypical
PKC on CRC cells proliferation and apoptosis. The treatment with ICA-I or ζ-Stat significantly reduced the proliferation of CRC cells (Figure 8). Likewise, LoVo and RKO

cells were undergoing apoptosis as evident by the visualization of apoptotic bodies (Figure 9(a)) and changes in the
expression of apoptotic and survival markers such as BCLXL, BCL-2, and survivin. The activation of Caspase cascade
is a critical event in a cell undergoing apoptosis [50]. PARP,
a nuclear enzyme, helps in DNA repair and maintain
genomic integrity in healthy cells. Cleaved PARP by active
Caspases is a marker of apoptotic cell death [51]. Caspase
cascade activation was confirmed by the change in the levels
of total and cleaved Caspase-3 and PARP (Figure 9(b,c)).
Further investigations need to be performed to decrypt the
whole apoptotic mechanisms in atypical PKC inhibitors
treated CRC cells.
Collectively, we can conclude that PKC-ζ is elevated in
both LoVo and RKO cells, PKC-ι is overexpressed in RKO
cell, and the atypical PKC when amplified or mutated are
implicated in the metastatic progression of CRC by regulating actin cytoskeleton of CRC cells via Cofilin activation
(Figure 10). Furthermore, the expression of atypical PKC
should be used as a biomarker for CRC when personalized
treatment is sought for anti-atypical PKC therapy.
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